## **INCRETIN RECEPTOR ENDOGENOUS** ATTENUATION OF DISEASE PROCESSES IN LIVER **AGONISM INCRETINS** Insulin **GIP Adipose** K **Inhibited** LCFAs & cells GLYCEROL Decreased PKC-ε GIP TAG release Akt-P **Dietary** nutrients **Pancreas** di-P PA DAG **Stimulated** Ceramide **INSULIN &** GLP-1 Inhibited cells LCFAs Glucose GLUCAGON secretion Brain GLP-1 **GLUCAGON** Reduced cells **VLDL Dietary** NUTRIENT ? GIP intake **GLUCOSE** nutrients K Decreased appetite and improved satiety cells Non alcoholic fatty liver disease **Decreased CHYLOMICRON synthesis and** 0 secretion with GLP-1RA treatment MetS features associated with NAFLD Liver **Incretin receptor Gut** and type 2 diabetes improved by responsive tissues **GLP-1RA** treatment

Fig. 2